CRISPR Therapeutics AG. (6/14/17). "Press Release: CRISPR Therapeutics to Present at the JMP Securities Life Sciences Conference". Basel & Cambridge, MA.

	Region	New York, NY
	Country	United States (USA)
	Organisation	CRISPR Therapeutics AG (Nasdaq: CRSP)
	Group	CRISPR Therapeutics (Group)
	Organisation 2	JMP Securities LLC
	Product	JMP Securities Life Sciences Conference 2017 New York
	Product 2	CRISPR gene editing technology
	Index term	CRISPR Therapeutics–JMP Securities: investor conference, 201706 supply service CRISPR Tx presents at JMP Securities 2017 Life Sciences Conference NY
	Index term 2	CRISPR Therapeutics–Westwicke Partners: public relations, 201703 service existent investor relations by Westwicke Partners
	Person	Kulkarni, Samarth (Sam) (CRISPR Therapeutics 201712– promoted CEO before CBO)
	Person 2	Paganelli, Jennifer (W2O Group 201703)

CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., President and Chief Business Officer of CRISPR Therapeutics, will present at the JMP Securities Life Sciences Conference at the St. Regis New York in New York, New York.

Event: JMP Securities Life Sciences Conference
Panel: Gene Editing – Pushing the Frontier for Curing Disease Editing
Date: Tuesday, June 20, 2017
Time: 9:00 AM

About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR / Cas9 gene-editing platform. CRISPR / Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR / Cas9 patent estate for human therapeutic use was licensed from the company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics AG is headquartered in Basel, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts. For more information, please visit http://www.crisprtx.com.

MEDIA CONTACTS:
Jennifer Paganelli
WCG on behalf of CRISPR
+1 347-658-8290 jpaganelli@wcgworld.com

INVESTOR CONTACT:
Chris Brinzey
Westwicke Partners for CRISPR
+1 339-970-2843 chris.brinzey@westwicke.com

Record changed: 2023-06-05